Comparing efficacy of two treatment methods including topical liposomal Amphotericin B versus intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
Phase 2
- Conditions
- Cutaneous leishmaniasis.Cutaneous Leishmaniasis
- Registration Number
- IRCT138802131871N1
- Lead Sponsor
- Research Council of Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Presence of cutaneous leishmaniasis approved by either a direct smear stained with Giemsa or a positive skin biopsy of lesions with less than 6 months duration, in cases of previous history of anti-leishmania therapy, a 3 month treatment free interval from the last treatment course
Exclusion criteria: Pregnancy, breast feeding, taking any other specific treatment while participating in the study, past medical history of any local or systemic disease during the last 2 months, presence of significant underlying disease such as cardiac, renal or liver dysfunction
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete healing. Timepoint: First time within 8 weeks after beginning of treatment and second one after 6 months after initiation of the intervention(s). Method of measurement: Measuring the size of induration and ulcer.
- Secondary Outcome Measures
Name Time Method Adverse Effects. Timepoint: Recorded at each follow-up visit. Method of measurement: Taking medical history and performing physical examination.